Literature DB >> 23709704

Novel methodologic approaches to phase I, II, and III trials.

Sharon D Yeatts1.   

Abstract

Entities:  

Keywords:  adaptive design; clinical trial design; continual reassessment method; futility design; selection design

Mesh：

Year:  2013        PMID： 23709704      PMCID： PMC3684044          DOI： 10.1161/STROKEAHA.111.000031

Source DB:  PubMed          Journal:  Stroke        ISSN： 0039-2499            Impact factor:   7.914


× No keyword cloud information.
  14 in total

1.  The neurology quality-of-life measurement initiative.

Authors:  David Cella; Cindy Nowinski; Amy Peterman; David Victorson; Deborah Miller; Jin-Shei Lai; Claudia Moy
Journal:  Arch Phys Med Rehabil       Date:  2011-10       Impact factor: 3.966

2.  Applying a phase II futility study design to therapeutic stroke trials.

Authors:  Yuko Y Palesch; Barbara C Tilley; David L Sackett; Karen C Johnston; Robert Woolson
Journal:  Stroke       Date:  2005-10-13       Impact factor: 7.914

3.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

4.  Design and analysis of phase I clinical trials.

Authors:  B E Storer
Journal:  Biometrics       Date:  1989-09       Impact factor: 2.571

5.  The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes.

Authors:  J F Fries; B Bruce; D Cella
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

Review 6.  New designs for the selection of treatments to be tested in randomized clinical trials.

Authors:  R Simon; P F Thall; S S Ellenberg
Journal:  Stat Med       Date:  1994 Mar 15-Apr 15       Impact factor: 2.373

7.  Calibrated phase II clinical trials in oncology.

Authors:  J Herson; S K Carter
Journal:  Stat Med       Date:  1986 Sep-Oct       Impact factor: 2.373

8.  A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.

Authors:  G Levy; P Kaufmann; R Buchsbaum; J Montes; A Barsdorf; R Arbing; V Battista; X Zhou; H Mitsumoto; B Levin; J L P Thompson
Journal:  Neurology       Date:  2006-03-14       Impact factor: 9.910

9.  Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.

Authors: 
Journal:  Stroke       Date:  2004-03-11       Impact factor: 7.914

10.  Measuring outcomes as a function of baseline severity of ischemic stroke.

Authors:  Harold P Adams; Jacques R Leclerc; Eric Bluhmki; William Clarke; Michael D Hansen; Werner Hacke
Journal:  Cerebrovasc Dis       Date:  2004-06-22       Impact factor: 2.762
View more
  8 in total

1.  Combination Therapies for Traumatic Brain Injury: Retrospective Considerations.

Authors:  Susan Margulies; Gail Anderson; Fahim Atif; Jerome Badaut; Robert Clark; Philip Empey; Maria Guseva; Michael Hoane; Jimmy Huh; Jim Pauly; Ramesh Raghupathi; Stephen Scheff; Donald Stein; Huiling Tang; Mona Hicks
Journal:  J Neurotrauma       Date:  2015-08-06       Impact factor: 5.269

2.  A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.

Authors:  Ruth B Schneider; Peggy Auinger; Christopher G Tarolli; Julia Iourinets; María Cristina Gil-Díaz; Irene H Richard
Journal:  Parkinsonism Relat Disord       Date:  2020-10-13       Impact factor: 4.891

3.  The futility study--Progress over the last decade.

Authors:  Bruce Levin
Journal:  Contemp Clin Trials       Date:  2015-06-26       Impact factor: 2.226

Review 4.  Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage.

Authors:  Adnan I Qureshi; Iryna Lobanova; Wei Huang; Muhammad F Ishfaq; Joseph P Broderick; Christy N Cassarly; Renee H Martin; R Loch Macdonald; Jose I Suarez
Journal:  Neurocrit Care       Date:  2021-12-23       Impact factor: 3.210

5.  Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.

Authors:  Gareth D James; Stefan N Symeonides; Jayne Marshall; Julia Young; Glen Clack
Journal:  BMC Cancer       Date:  2016-08-31       Impact factor: 4.430

Review 6.  Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials.

Authors:  Jing Zhang; Yuan Zong; Gang-Zhu Xu; Ke Xing
Journal:  Saudi Med J       Date:  2016-11       Impact factor: 1.484

7.  Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.

Authors:  G D James; S Symeonides; J Marshall; J Young; G Clack
Journal:  BMC Cancer       Date:  2021-01-05       Impact factor: 4.430

8.  Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients.

Authors:  Guangyi Gao; Byron J Gajewski; Jo Wick; Jonathan Beall; Jeffrey L Saver; Caitlyn Meinzer
Journal:  Trials       Date:  2022-09-06       Impact factor: 2.728
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.